Higher-Dose Infliximab Induction Achieves Better Maintenance Trough Levels in a National Pediatric IBD Cohort—A Retrospective Study
Our real-world data show that 5 mg/kg infliximab induction does not achieve target TLs in most children with CD. Higher-dose regimens should be considered, especially if proactive therapeutic drug monitoring is not available.
Authors
- Donya Al‐Hassan (ORCID: https://orcid.org/0000-0001-6753-0901)
- Emer Fitzpatrick (ORCID: https://orcid.org/0000-0002-1364-5305)
- Connor J. Cooper (ORCID: https://orcid.org/0000-0002-5527-9948)
- Emily Stenke (ORCID: https://orcid.org/0000-0002-4101-4383)
- Séamus Hussey (ORCID: https://orcid.org/0000-0002-9362-0465)
- Ciara Lang
- Lorraine Stallard (ORCID: https://orcid.org/0000-0002-1280-6525)
- Annemarie Broderick (ORCID: https://orcid.org/0000-0002-6001-4151)
- Billy Bourke (ORCID: https://orcid.org/0000-0003-1833-8694)
- Shoana Quinn (ORCID: https://orcid.org/0000-0001-6809-7839)
- Molly Moclair
- Anna Dominika
Institutions
- University College Dublin (IE)
- Royal College of Surgeons in Ireland (IE)
- Children's Health Ireland at Crumlin (IE)
Publication Details
- Journal
- Inflammatory Bowel Diseases
- Published
- 2025-02-26
- DOI
- https://doi.org/10.1093/ibd/izaf031
- Citations
- 1
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 1.82